Factor XII-Dependent Fibrinolysis: A Double Function of Plasma Kallikrein and the Occurrence of a Previously Undescribed Factor XII- and Kallikrein-Dependent Plasminogen Proactivator^[*]

Summary

Fibrinolytic studies in euglobulin fractions of Fletcher trait plasma (deficient in prekallikrein) revealed reduced activities as compared to normal plasma. A quantitative assay for total plasminogen activator plus proactivator in plasma showed that the amount in Fletcher trait patients is about half of normal (normal = ± 100 blood activator units [BAU]/ ml). Plasma kallikrein partially purified in a high and low molecular weight form exerted plasminogen activator activity amounting to 10–15 BAU/ml plasma. So, the absence of kallikrein in the deficient plasma can not fully account for the reduction in activator activity. Additions of kallikrein preparations or normal plasma fractions resulted in additional activator activity in Fletcher trait plasma which was assessed at 30–40 BAU/ml. This activity was assumed to originate from a previously undescribed plasminogen proactivator whose activation is kallikrein- and factor XH-dependent.

Fractionation experiments demonstrated the presence of two major activities and a minor activity caused by kallikrein in normal plasma.

It is concluded that plasma kallikrein has two functions in the generation of factor XII- dependent fibrinolytic activity: one as a direct plasminogen activator and another as a factor in the activation of a major factor XH-dependent plasminogen proactivator.

• References

• 1 Astrup T, ROSA AT. 1974; A plasminogen proactivator-activator system in human blood effective in absence of Hageman Factor. Thrombosis Research 4: 609
• 2 Bouma BN, Griffin JH. 1978; Deficiency of factor XH-dependent plasminogen proactivator in prekallikrein-deficient plasma. Journal of Laboratory and Clinical Medicine. 91: 148
• 3 Brakman P. 1967. Fibrinolysis. A standardized fibrin plate method and a fibrinolytic assay of plasminogen.. Thesis. Scheltema and Holkema; Amsterdam:
• 4 Colman RW. 1969; Activation of plasminogen by human plasma kallikrein. Biochemical and Biophysical Research Communications 35: 273
• 5 Donaldson VH, Kleniewski J, Saito H, Sayed JK. 1977; Prekallikrein deficieny in a kindred with kininogen deficiency and Fitzgerald trait clotting defect. Journal of Clinical Investigations 60: 571
• 6 Goldsmith G, Saito H, Ratnoff OD. 1977; The activation of plasminogen by Hageman factor and Hageman factor fragments. Thrombosis and Haemostasis 38: 136
• 7 Griffin JH. 1977; Molecular mechanisms of contact activation. Thrombosis and Haemostasis. 38: 117
• 8 Hattersley PG, Hayse D. 1970; Fletcher factor deficiency: A report of three unrelated cases. British Journal of Haematology 18: 411
• 9 Haverkate F, Brakman P. 1915. Fibrin plate assay. In: Davidson JF, Samama MM, Desnoyers PC. (eds.) Progress in Chemical Fibrinolysis and Thrombolysis Raven Press; New York: 1 151
• 10 Herbert RG, Ogston D, Douglas AS. 1972; Further purification and properties of Hageman factor cofactor. Biochimica et Biophysica Acta 217: 371
• 11 Iatridis SG, Ferguson JH. 1962; Active Hageman factor: A plasma lysokinase of the human fibrinolytic system. Journal of Clinical Investigations 41: 1277
• 12 Iatridis PG, Ferguson JH. 1965; Plasminoplastin generation test of normal, HF-, PTA-, X-, PTC-, and AHF- platelet-poor plasmas: Evidence that only HF- plasma has an abnormal fibrinolytic activity. Nature 217: 1404
• 13 Kaplan AP, Austen KF. 1972; The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. Journal of Experimental Medicine 136: 1378
• 14 Kaplan AP, Goetzl ET, Austen KF. The fibrinolytic pathway of human plasma. Generation of chemotactic activity by activation of plasminogen proactivator. 2
• 15 Kluft C, Brakman P, Veldhuyzen-Stolk EC. 1976. Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Davidson JF, Samama MM, DESNOYERS PC. (eds.) Progress in Chemical Fibrinolysis and Thrombolysis. Raven Press New York; 2 57
• 16 Kluft C. 1977; An inventory of plasminogen activators in human plasma. Thrombosis and Haemostasis 38: 134
• 17 Kluft C, Jenks RL, Astrup T. 1977; Production of plasminogen activator activity in factor XH-deficient plasma. Thrombosis Research 10: 759
• 18 Kluft C. 1978; a Determination of prekallikrein in human plasma: Optimal conditions for activating prekallikrein. Journal of Laboratory and Clinical Medicine 97: 183
• 19 Kluft C. 1978. b Levels of plasminogen activators in human plasma: New methods to study the intrinsic and extrinsic activators. Davidson TF, Rowan RM, Samama MM, Desnioyers PC. eds. In: Progress in Chemical Fibrinolysis and Thrombolysis Raven Press; New York: 3 141
• 20 Laake K, Vennerod AM. 1974; Factor XH-induced firbrinolysis: Studies on the separation of prekallikrein, plasminogen proactivator and factor XI in human plasma. Thrombosis Research 4: 285
• 21 Laurell CB. 1966; Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Analytical Biochemistry 75: 45
• 22 Mancini G, Carbonara AO, Heremans JF. 1965; Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 2: 235
• 23 Mandle Jr R, Colman RW, Kaplan AP. 1976; Identification of prekallikrein and high molecular weight kininogen as a complex in human plasma. Proceedings of the National Academy of Sciences USA 72: 4179
• 24 Mandle R, Kaplan AP. 1977; Hageman factor substrates. Human plasma prekallikrein: Mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. Journal of Biological Chemistry 252: 6097
• 25 Meier HL, Pierce JV, Colman RW, Kaplan AP. 1977; Activation and function of human Hageman factory. The role of high molecular weight kininogen and prekallikrein.. Journal of Clincal Investigation 60: 18
• 26 Nagasawa S, Nakayasu T. 1973; Human plasma prekallikrein as a protein complex. Journal Biochemistry 74: 401
• 27 Niewiarowski S, Prou-Wartelle O. 1959; Role du facteur contact (Facteur Hageman) dans la fibrinolyse. Thrombosis et Diathesis Haemorrhagica 3: 593
• 28 Ogston D, Ogston CM, Ratnoff OD, Forbes CD. 1969; Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: The participation of Hageman factor and additional cofactors. Journal of Clinical Investigations 48: 1786
• 29 Ogston D, Bennett B, Mackie M. 1976; Properties of a partially purified preparation of a circulating plasminogen activator. Thrombosis Research 8: 275
• 30 Revak SD, Cochrane CE, Griffin JH. 1977; The binding and cleavage characteristics of human Hageman factor during contact activation. Journal of Clinical Investigation 59: 1167
• 31 Saito H, Ratnoff OD, Donaldson VH. 1974; Defective activation of clotting, fibrinolytic and permeability-enhancing systems in human Fletcher trait plasma. Circulation Research 34: 641
• 32 Trumpi-Kalshoven MM, Kluft C, Jie AF H. 1977; Cl-inactivator as the main inhibitor of high molecular weight human plasma kallikrein. 11th FEBS Meeting Copenhagen Abstract A6-6 865
• 33 Vennerod AM, Laake K. 1976; Prekallikrein and plasminogen proactivator: Absence of plasminogen proactivator in Fletcher factor deficient plasma. Thrombosis Research 8: 519
• 34 Weiss AS, Gallin JI, Kaplan AP. 1974; Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. Journal of Clinical Investigations 53: 622
• 35 Wendel U, Vogt W, Seidel G. 1972; Purification and some properties of a kininogenase from human plasma activated by surface contact. Hoppe-Seyler’s Zeitschrift fiir physiologische Chemie 353: 1591
• 36 Wuepper KD. 1973; Prekallikrein deficiency in man. Journal of Experimental Medicine 138: 1345
• 37 Wuepper KD. 1973; Prekallikrein-Hageman factor cofactor-Fletcherfactor: Are they identical. Clinical Research 21: 484